With immune checkpoint inhibitors (ICIs) becoming the mainstay of treatment for many
cancers, managing their immune-related adverse events (irAEs) has become an important …

The process of neutrophil extracellular traps (NETs) formation, called NETosis, is a peculiar
death modality of neutrophils, which was first observed as an immune response against …

It's been long thought that CD8+ cytotoxic T cells play a major role in T cell‐mediated
antitumor responses, whereas CD4+ T cells merely provide some assistance to CD8+ T …

Lung cancer is a major global health issue, and despite major strides made in diagnostic
and treatment modalities, outcomes for patients with NSCLC still present significant …

Immune checkpoint inhibitor (ICI) therapy, a novel anti-tumor strategy, can specifically
eliminate tumors by activating the immune system and inhibiting tumor immune escape …

Immune checkpoint inhibitors (ICIs) activate T cells, causing immune-related adverse events
(irAEs). Skin manifestations are common among irAEs, but ICI-associated bullous …

Predictive biomarkers for immune checkpoint inhibitors (ICI), such as PD-L1 expression
(TPS), remain limited in clinical applications. Improved novel ICI predictive biomarkers are …

The evolving landscape of immune-related adverse events that follow immune checkpoint
immunotherapy in cancer patients